Cardiovascular Risk Evaluation in Psoriatic Arthritis by Aortic Stiffness and the Systemic Coronary Risk Evaluation (SCORE): Results of the Prospective PSOCARD Cohort Study Konstantinos TriantafylliasStefanie LiverakosAndreas Schwarting Original Research Open access 31 May 2024
Drug Persistence and Incidence of Active Tuberculosis of Tumor Necrosis Factor Alpha Inhibitors Versus Tocilizumab as the First-Line Biological Treatment in Patients with Rheumatoid Arthritis: A Nationwide Population-Based Retrospective Cohort Analysis Min Wook SoA-Ran KimSeung-Geun Lee Original Research Open access 20 May 2024
Correction: Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1) Hideto KamedaKohei HagimoriHiroaki Dobashi Correction Open access 16 May 2024
Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data Lars Erik KristensenAtul DeodharDafna D. Gladman Commentary Open access 02 May 2024 Pages: 487 - 499
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials Gerd R. BurmesterJayne StiglerLianne S. Gensler Original Research Open access 29 April 2024 Pages: 737 - 753
Population Pharmacokinetics of the Anti-Interferon-Gamma Monoclonal Antibody Emapalumab: An Updated Analysis Patrick BrossardChristian Laveille Brief Report Open access 25 April 2024 Pages: 869 - 880
Elevating the Standard of Care for Patients with Psoriatic Arthritis: ‘Calls to Action’ from a Multistakeholder Pan-European Initiative Iris VerbinnenEmilio Monte-BoquetPhilip S. Helliwell Original Research Open access 25 April 2024 Pages: 795 - 815
Elevating the Standard of Care for Patients with Axial Spondyloarthritis: ‘Calls to Action’ from Rheumacensus, a Multistakeholder Pan-European Initiative Andri PhokaBart J. F. van den BemtXenofon Baraliakos Original Research Open access 25 April 2024 Pages: 773 - 794
A Phase 1a Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7303509, an Anti-TGFβ3 Antibody, in Healthy Volunteers Lyrialle W. HanSamira JamalianSara Glickstein Original Research Open access 25 April 2024 Pages: 755 - 771
A Machine Learning Approach for Prediction of CDAI Remission with TNF Inhibitors: A Concept of Precision Medicine from the FIRST Registry Koshiro SonomotoYoshihisa FujinoYoshiya Tanaka Original Research Open access 18 April 2024 Pages: 709 - 736
Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial Kurt de VlamWalter P. MaksymowychPhilip G. Conaghan Original Research Open access 18 April 2024 Pages: 691 - 707
Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies Alan J. KivitzJoel M. KremerAtul Singhal Original Research Open access 16 April 2024 Pages: 675 - 689
Clinical Characteristics of “Severe” Peripheral Psoriatic Arthritis: A Retrospective Analysis of a Longitudinal Cohort Ennio LubranoSilvia ScriffignanoFabio Massimo Perrotta Original Research Open access 09 April 2024 Pages: 663 - 674
Current Use and Barriers to Point-of-Care Ultrasound in Rheumatology: A National Survey of VA Medical Centers Ayesha IqbalMadiha AhmadNilam J. Soni Brief Report Open access 06 April 2024 Pages: 855 - 867
Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting Joshua F. BakerCatherine BakewellKarim R. Masri Brief Report Open access 20 March 2024 Pages: 841 - 853
Long-Term Efficacy Following Intra-articular Injection of Carboxymethyl-chitosan, a New Product Class for Knee Osteoarthritis: Results from an Observational Study in Germany Nils A. LynenChristoph EichhornWim Weyenberg Original Research Open access 18 March 2024 Pages: 649 - 662
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial Andrew ÖstörFilip Van den BoschAlan Kivitz Original Research Open access 18 March 2024 Pages: 633 - 648
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial Lars Erik KristensenMauro KeisermanFrank Behrens Original Research Open access 18 March 2024 Pages: 617 - 632
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE Roy FleischmannRicardo BlancoEduardo Mysler Original Research Open access 18 March 2024 Pages: 599 - 615
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison Richard B. WarrenIain B. McInnesPhilip J. Mease Brief Report Open access 15 March 2024 Pages: 829 - 839
Long-term Etanercept Response for Patients with Radiographic Axial Spondyloarthritis Based on Achievement of Early, Intermediate, or Late Responses During Index Studies Xenofon BaraliakosAnnette E. SzumskiCecilia E. Borlenghi Original Research Open access 15 March 2024 Pages: 583 - 597
Real-World Effectiveness of Upadacitinib for Treatment of Rheumatoid Arthritis in Canadian Patients: Interim Results from the Prospective Observational CLOSE-UP Study Louis BessetteJonathan ChanDerek Haaland Original Research Open access 11 March 2024 Pages: 563 - 582
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison Philip J. MeaseRichard B. WarrenIain B. McInnes Brief Report Open access 06 March 2024 Pages: 817 - 828
Assessment of Patient–Physician Interactions in Psoriatic Arthritis: National Results of the ASSIST Study Fabio Massimo PerrottaRossana ScrivoEnnio Lubrano Original Research Open access 06 March 2024 Pages: 553 - 562
The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre “Real-Life” Cohort Study Piero RuscittiGiulia CataldiPaola Cipriani Original Research Open access 04 March 2024 Pages: 539 - 551
Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases Ran JinSilvia KruppertJonathan Kay Original Research Open access 04 March 2024 Pages: 523 - 537
Neutrophilic Activity Biomarkers (Plasma Neutrophil Extracellular Traps and Calprotectin) in Established Patients with Rheumatoid Arthritis Receiving Biological or JAK Inhibitors: A Clinical and Ultrasonographic Study Beatriz Frade-SosaAndrés PonceRaimon Sanmarti Original Research Open access 02 March 2024 Pages: 501 - 521
Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials Pushpike ThilakarathneAgata SchubertFareen Hassan Original Research Open access 28 February 2024 Pages: 457 - 474
Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study Vinod ChandranLouis BessetteJohn S. Sampalis Original Research Open access 28 February 2024 Pages: 443 - 455
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis Jeffrey R. CurtisIain B. McInnesPhilip J. Mease Original Research Open access 22 February 2024 Pages: 425 - 441
Reproductive Effect by Rheumatoid Arthritis and Related Autoantibodies Ping-Fen LiShan LiPeng-Sheng Zheng Review Open access 20 February 2024 Pages: 239 - 256
Reliability Exercise of Ultrasound Salivary Glands in Sjögren’s Disease: An International Web Training Initiative Baptiste QuéréAlain SarauxSandrine Jousse-Joulin Original Research Open access 19 February 2024 Pages: 411 - 423
Thermography at the Elbow Among Patients with Rheumatoid Arthritis: A Comparison with Ultrasound-Detected Joint Inflammation Findings York Kiat TanRehena SultanaJulian Thumboo Brief Report Open access 15 February 2024 Pages: 475 - 485
Anemia and Low Body Mass Index in Axial Spondyloarthritis: Results from ChinaSpA, the Chinese Spondyloarthritis Registry Hailong LiQingyang LiXiang Gao Original Research Open access 13 February 2024 Pages: 397 - 409
Safety and Efficacy of Hybrid Cooperative Complexes of Sodium Hyaluronate and Sodium Chondroitin for the Treatment of Patients with Symptomatic Knee Osteoarthritis Cristiano SconzaDario RomanoBerardo Di Matteo Original Research Open access 12 February 2024 Pages: 381 - 395
Real-World Use and Effectiveness Outcomes in Patients with Rheumatoid Arthritis Treated with Upadacitinib: An Analysis from the CorEvitas Registry Joshua F. BakerPatrick ZuegerRobert R. McLean Original Research Open access 12 February 2024 Pages: 363 - 380
Emerging Role of Interleukin-38 (IL-38) in the Development of Rheumatoid Arthritis Shengxiang LiangLiting ChenMin Yang Original Research Open access 05 February 2024 Pages: 349 - 362
Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE Eugen FeistXenofon BaraliakosThomas Meng Original Research Open access 03 February 2024 Pages: 331 - 348
Efficacy and Safety of Risankizumab in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Qin-Yi SuHao-Nan ZhouSheng-Xiao Zhang Review Open access 01 February 2024 Pages: 227 - 237
Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Philip J. MeasePamela YoungAlexis Ogdie Original Research Open access 22 January 2024 Pages: 313 - 329
Social Listening in Gout: Impact of Proactive vs. Reactive Management on Self-Reported Emotional States Maurice FlurieMonica ConverseMaria Picone Original Research Open access 22 January 2024 Pages: 301 - 311
The Impact of Systemic Lupus Erythematosus Flares on Clinical and Economic Outcomes: The CHAMOMILE Claims Database Study in Germany Bo DingMarc PignotAndreas Schwarting Original Research Open access 22 January 2024 Pages: 285 - 299
Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis Han XieYuan ZhangWeihong Ge Original Research Open access 18 January 2024 Pages: 269 - 283
Impact of the COVID-19 Pandemic on People Living with Rheumatoid Arthritis: Experiences and Preferences in Accessing Healthcare Across Five Countries Alain SarauxLicia Maria Henrique da MotaMeriem Kessouri Original Research Open access 13 January 2024 Pages: 257 - 268
Characteristics of COVID-19 and Impact of Disease Activity in Patients with Adult-Onset Still’s Disease Xinyue HongXiaoming WangHuihui Chi Brief Report Open access 06 January 2024 Pages: 201 - 212
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years Christina Charles-SchoemanJon T. GilesIain B. McInnes Original Research Open access 05 January 2024 Pages: 157 - 175
Safety and Efficacy of Inactivated SARS-CoV-2 Vaccine in Patients with Rheumatic Diseases and Serum Antibody Changes Post-Omicron Variant Infection Xiaowei ZhangYifei LiGuihong Wang Brief Report Open access 04 January 2024 Pages: 191 - 200
The Role of Early Treatment in the Management of Axial Spondyloarthritis: Challenges and Opportunities Daniele MauroGiulio ForteFrancesco Ciccia Review Open access 18 December 2023 Pages: 19 - 34
Adalimumab Effectively Decreases Inflammation Downstream of TNFα Signaling in Synoviocytes from Extended Oligoarticular Juvenile Idiopathic Arthritis Megan M. SimondsSamuel T. FreerAnneMarie C. Brescia Original Research Open access 09 December 2023 Pages: 143 - 155
Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis Jeffrey R. CurtisPaul EmeryGerd Rüdiger Burmester Brief Report Open access 06 December 2023 Pages: 177 - 189